|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK20 was more sensitive for the diagnosis of bladder urothelial carcinoma (BUC) than all types of BC (0.83 vs 0.75).
|
29931834 |
2019 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, it has been suggested that the immunohistochemical expressions of only two markers, luminal (CK20+, CK5/6-) and basal (CK5/6+, CK20-), is sufficient to identify the molecular subtypes of bladder cancer.
|
31240474 |
2019 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
At least two markers (MRE11 and CK20) were significantly associated with survival in patients with bladder cancer, and a further three markers showed results warranting expert follow-up.
|
29991697 |
2018 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers, including p53, Ki-67, and CK20, with classic and prognostic factors with recurrence and novel markers such as EN2 may provide a more accurate prediction of outcome compared with any single marker, improving risk stratification and clinical management of patients with BCa.
|
26574637 |
2017 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 bladder cancer.
|
28074276 |
2017 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CK20 mRNA as confirmed marker of bladder cancer was also assayed.
|
28888400 |
2017 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of IGF2 and CK20 enabled the detection of BCa with a diagnostic performance similar to VUC.
|
28484844 |
2017 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the sensitivity and specificity of combined detection with CK20 and FGFR1 for the differentiation between invasive and non-invasive stages of bladder cancer reached 97.5% and 92.5%, respectively.
|
27259667 |
2016 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative assessment of tumor-related transcript markers, particularly of CK20, may serve as a noninvasive method to identify patients with BCa.
|
26328914 |
2016 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of cytokeratin 20 was always significantly higher in patients with bladder cancer when compared with that in both the tumor-free groups.
|
26282902 |
2015 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages.
|
21190793 |
2011 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we describe the isolation and characterization of a tumor-initiating cell (T-IC) subpopulation in primary human bladder cancer, based on the expression of markers similar to that of normal bladder basal cells (Lineage-CD44(+)CK5(+)CK20(-)).
|
19666525 |
2009 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
|
18804101 |
2008 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.
|
18026991 |
2008 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
|
18804101 |
2008 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Dysregulation of CK20 expression is an early event in the carcinogenesis of papillary noninvasive bladder cancer, but occurs later than FGFR3 mutations.
|
17240035 |
2007 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dysregulation of CK20 expression is an early event in the carcinogenesis of papillary noninvasive bladder cancer, but occurs later than FGFR3 mutations.
|
17240035 |
2007 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, four of the differentially expressed genes in microarrays related to bladder cancer (KRT20, IGF2, GSN, and CCL2) were analyzed in 36 tumoural and 14 control BW samples by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).
|
16815626 |
2006 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymph node CK 20 RT-PCR correlates with pathological stage in bladder cancer.
|
16475726 |
2006 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overall sensitivity of CK-20 gene expression in voided urine samples for the detection of bladder neoplasms was 78%.
|
12478110 |
2003 |
|
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using this optimal procedure, we examined CK20 mRNA expression in ten epithelial and seven leukemic cell lines, in eight bladder tumors, in peripheral blood samples from 18 tumor patients and from 29 healthy controls and in 8 bone marrow samples from healthy donors.
|
10470150 |
1999 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK-20 amplification band (370 base pairs) was obtained with messenger ribonucleic acid extracted from transitional cell carcinoma cells of bladder tumor.
|
9817302 |
1998 |
|
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CK-20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT-29 line (a CK-20 colon carcinoma line).
|
9445193 |
1998 |